Skip to Content

Cell therapy improves progression-free survival with 50% in advanced melanoma

At ESMO 2022, the first randomized phase 3 trial to investigate T-cell therapy in solid advanced tumors in patients with advanced melanoma is presented. Results suggest that treatment with tumor-infiltrating lymphocytes (TIL) significantly improves progression-free survival when compared to ipilimumab (IPI). Get the full presentation from Professor John Haanen in this MEDtalk.

John Haanen

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top